Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).

Additionally, at week 12, 6.3% of patients receiving tildrakizumab 100 mg and 9.7% receiving tildrakizumab 200 mg achieved PASI 100 compared with 3.1% receiving placebo, but this difference did not reach statistical significance (both nominal P > 0.05).

also in 111,027 other papers